Introducing VISUALIZE: Real-World Myeloma Evidence, Ready When You Ask
Multiple myeloma is a disease of many lines of therapy, shifting responses and long patient journeys. Yet much of the real-world data used to study it is thin, pieced together from billing codes and claims that say a drug was dispensed, but not how the patient actually responded.
Today we're introducing VISUALIZE, All4Cure's real-world myeloma evidence platform. It brings clinician-abstracted patient data, at a depth rarely seen in real-world evidence, into an interface where you can ask a question in plain language and get an answer in seconds.
Real-world myeloma data at unprecedented depth
VISUALIZE captures every line of therapy, every response and every lab for each patient. That data is abstracted from the medical record by clinicians, not inferred from billing.
The result is a longitudinal view of myeloma care that claims data alone can't provide:
Cohort at a glance | |
Patients with multiple myeloma | 1,160+ |
Mean follow-up | ~6.4 years |
Lines of therapy on record | 3,964 |
With more than six years of average follow-up, you can see not just what happened on first-line therapy, but how patients moved through relapse, re-treatment and beyond.
Every patient, every regimen: inside VISUALIZE
VISUALIZE puts the full cohort at your fingertips, from population-level trends down to a single patient's journey.
Chat with the data. Ask a question in plain language. Seconds later you get the answer, along with the definitions behind it, so you always know exactly what was measured.
Response depth. See the best IMWG response recorded on every line of therapy across the cohort, from stringent complete response (sCR) through progressive disease (PD).
Outcomes. Explore time to next treatment (TTNT) by line, measured from the start of each line to the next line or death, with patients at risk shown.
Regimens. Compare every regimen side by side: patients, months on regimen, response rates and median time to next treatment.
Regimen flow. Follow the cohort from line to line and see how treatment sequences actually unfold in practice.
Patient detail. Drill down to an individual de-identified patient to see their full therapy history, response at every line and how they compare with cohort benchmarks.
Trust built in
Every record in VISUALIZE comes from a patient who chose to share it. The patients in this cohort partnered in their own care and consented to contribute their data to advance myeloma research.
Consented and governed. Data is accessed under governed, controlled conditions.
De-identified, with dates shifted. Patient privacy is protected at every level of the platform, including the single-patient view.
No BAA required. Because the data is de-identified, engagements don't require a Business Associate Agreement, so your team can get started faster.
Two ways to work with VISUALIZE
Whether your team wants hands-on access or a finished analysis, there's a path that fits.
VISUALIZE Access | Sponsored Analyses | |
What it is | A 12-month license to the platform | Custom studies run by All4Cure data scientists |
How you use it | Explore the dataset directly through the interface | Define the question; we do the analysis |
What you get | Self-serve answers, charts and patient-level detail | A detailed written report |
Best for | Teams that want to explore and iterate on their own | Teams that need a specific, rigorous answer |
Real-world myeloma evidence, ready when you ask
VISUALIZE turns years of clinician-abstracted, patient-consented data into answers your team can use today, whether you're shaping a development program, building a value story or studying treatment sequencing.
Ready to see it for yourself? Contact our team to talk about VISUALIZE Access or a Sponsored Analysis.
